Evaluation of a novel micro/nanofluidic chip platform for the detection of influenza A and B virus in patients with influenza-like illness

AMB Express

Table 3 Results of the MNCP assay for influenza A and B virus detection and compared with the rRT-PCR test

Virus	No. detected (MNCP/rRT-PCR)^a				Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPVs (%) (95% CI)	NPVs (%) (95% CI)	Overall concordance rate (%) (95% CI)	P value (McNemar’s test)	Kappa value (95% CI)
Virus	+/+	+/−	−/+	−/−	Sensitivity (%) (95% CI)	Specificity (%) (95% CI)	PPVs (%) (95% CI)	NPVs (%) (95% CI)	Overall concordance rate (%) (95% CI)	P value (McNemar’s test)	Kappa value (95% CI)
Influenza A	89	5	1	160	98.89 (93.10 − 99.94)	96.97 (92.70 − 98.88)	94.68 (87.45 − 98.03)	99.38 (96.07 − 99.97)	97.65 (94.70 − 99.04)	0.219	0.95** (0.91 − 0.99)
Influenza B	94	1	5	159	94.95 (88.06 − 98.13)	99.38 (96.04 − 99.97)	98.95 (93.44 − 99.95)	96.95 (92.65 − 98.87)	97.68 (94.78 − 99.05)	0.219	0.95** (0.91 − 0.99)

+: positive; −: negative; MNCP: micro/nanofluidic chip platform; rRT-PCR: real-time reverse transcription polymerase chain reaction; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value
**P < 0.001 (kappa statistics)
^aMNCP and rRT-PCR were conducted successively in 255 of 266 patients to detect influenza A virus (11 were excluded because of sample volume shortage) and in 259 of 266 patients to detect influenza B virus (seven excluded because of sample volume shortage)